On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on ...

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on ...

Pfizer Philippines, together with healthcare professionals, has launched "For the Reasons that Matter", a public awareness campaign focused on adult respiratory health. Rolling out across the ...

Investors who seek out dividend stocks pay close attention to a company's dividend yield, and high-yield players -- as long ...

The Full Court of the Federal Court of Australia (Justices Beach, Downes and Jackman) has held that the relevant date for ascertaining the "knowledge element" of the best method requirement under ...

Pfizer has settled patent disputes with Cipla, Dexcel Pharma, and Hikma Pharmaceuticals over Vyndamax, extending U.S. exclusivity to June 1, 2031. The deal averts earlier generic entry and stabilizes ...

Pfizer has reached settlements with three drugmakers to delay US generic competition for its $6.4 billion heart drug Vyndamax until 2031, extending revenue stability amid looming industry pressures.

Republican Wisconsin Sen. Ron Johnson held a hearing probing Biden officials over the handling of COVID-19 vaccine safety ...

BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, ...